

Table 1. OC-PDXs derived at FCCC

	Case	Spec #	Mo/yr implt	Dx	Type	Harvest site specimen	P <sub>0</sub>	≥P <sub>1</sub>	1° or recurr	Neo or Adj Thx	Known post-op recurrence	platinum sensitivity	BRCA	aCGH	RNaseq	cell line J2 - feeders
1	OC-1	2000400 1010058	Nov-12	Adenocarcinoma, NOS	Asc	Para	✓	✓	R	N				Pt, PDX	PDX, cell line	✓
2	OC-2	1013983	Nov-12	Cystadenocarcinoma	T	OM	✓	✓	P	N	(9/2013) <sup>PR</sup>	resistant				
3	OC-8	1014315	Feb-13	Serous cystadenocarcinoma	T	OV	✓	✓	P	N	(10/2013)	likely resistant		Pt, PDX		
4	OC-10	1014388	Mar-13	Serous cystadenocarcinoma	T	OM	✓	✓	P	N		sensitive	BRCA1/2 neg			
5	OC-14	2000429 1012761	Apr-13	Cystadenocarcinoma	Asc	para	✓	✓	R	A	✓	resistant	BRCA1/2 neg	Pt, PDX	Pt, PDX	
6	OC-16	1014776	Jul-13	Serous cystadenocarcinoma		OV	✓	✓	P	N	(2/2014)	likely resistant		Pt, PDX	Pt, PDX, cell line	✓
7	OC-18	1014836	Jul-13	Serous cystadenocarcinoma	T	OM	✓	✓	P	N	(2/2014)	resistant	BRCA1/2 neg			
8	OC-20	1014865	Aug-13	Serous cystadenocarcinoma	T	OM	✓	✓	P	A		sensitive		Pt, PDX	Pt, PDX, cell line	✓
9	OC-22	1015020	Oct-13	Adenocarcinoma, NOS	T	OV	✓	✓	P	N	progressed	refractory				
10	OC-24	2000451	Nov-13	Adenocarcinoma, NOS	Asc	Para	✓	✓	R		never disease free	refractory	BRCA1/2 neg			✓
11	OC-27	1015264	Jan-14	Adenocarcinoma, NOS	T	OV	✓	✓	P	N	(1/2015)	sensitive				
12	OC-29	1015319	Jan-14	Serous cystadenocarcinoma	T	OV	✓	✓	P	N	(9/2014)	resistant	BRCA1/2 neg	Pt, PDX	Pt, PDX, cell line	✓
13	OC-32	2000462	Mar-14	Serous cystadenocarcinoma	Asc	para	✓	✓	R	(N)	(9/2012)	initially sensitive	BRCA1/2 neg			
14	OC-33	1015473	Mar-14	Serous cystadenocarcinoma	T	OV	✓	✓	P	A		sensitive	BRCA1 & p53 mut			
15	OC-34	1015482	Mar-14	Mixed cell adenocarcinoma	T	OV	✓	✓	P	A		sensitive	BRCA1/2 neg			
16	OC-35	1015502	Mar-14	Serous cystadenocarcinoma	T	OV	✓		P	A		sensitive	BRCA1/2 neg			
17	OC-37	1015543	Mar-14	Serous cystadenocarcinoma	T	OV	✓	✓	P	A	(2/2015)	resistant				
18	OC-38	1015547	Mar-14	Adenocarc (NOS) ovarian (frmly CRC)	T	OV	✓	✓				sensitive	BRCA1/2 neg	Pt, PDX	Pt, PDX, cell line	✓
19	OC-40	1015578	Apr-14	Serous cystadenocarcinoma	T	OV	✓	✓	P	A		sensitive				
20	OC-41	1015579	Apr-14	Mixed cell adenocarcinoma	T	OV	✓	✓	P	A		sensitive				
21	OC-42 OC-42a	1015595	Apr-14	Serous cystadenocarcinoma	T/Asc	OV	✓	✓	P	A		sensitive	BRCA1/2 neg	Pt, PDX-s, PDX-asc	Pt, PDX-s, PDX-asc	
22	OC-44	1015696	May-14	Clear cell adenocarcinoma	T	OV	✓		P	N	(11/2014)	resistant				
23	OC-45	1105698	May-14	Serous cystadenocarcinoma	T	OM	✓	✓	P	N	(10/2015)	sensitive	BRCA1/2 neg			
24	OC-46	1015700	May-14	Serous cystadenocarcinoma	T	OV	✓	✓	P	A		sensitive	BRCA1/2 neg			
25	OC-49	2000469	May-14	Serous cystadenocarcinoma	Asc	para	✓	✓	R	A	✓(9/2011)	initially sensitive		PDX	Pt, PDX, cell line	✓
26	OC-58	1015880	Jun-14	Serous cystadenocarcinoma	T	OV	✓	✓	P	A		sensitive				
27	OC-59	1015912	Jun-14	Serous cystadenocarcinoma	T	OV	✓		P	N	progressed (10/14)	refractory	BRCA1/2 neg			
28	OC-60	1015926	Jul-14	Serous cystadenocarcinoma	T	OV	✓	✓	P	A	(4/2015)	resistant	BRCA1/2 neg	Pt, PDX	Pt, PDX	✓
29	OC-63	1015994	Jul-14	mixed Müllerian	T	OV	✓	✓	P	A		sensitive				✓
30	OC-67	1016118	Sep-14	carcinosarcoma, NOS	T		✓	✓	P	A	(4/2015)	resistant				
31	OC-68	1016193	Sep-14	Papillary serous cystadenocarcinoma	T		✓	✓	P	N		sensitive	BRCA1/2 neg			
32	OC-69	1016228	Oct-14	Serous cystadenocarcinoma	T	OV	✓		P	N		resistant	BRCA1/2 neg			
33	OC-76	1016355	Nov-14	endometrioid synch. ovary and endometrial	T		✓	✓	P	A		sensitive				✓
34	OC-81	1016470	Dec-14	Clear cell adenocarcinoma	T		✓		P	A	(4/2015)	refractory				
35	OC-91	1016746	Mar-15	Serous cystadenocarcinoma	T		✓		P	A		sensitive				
36	OC-92	2000571	Mar-15	endometrioid adenocarcinoma, NOS	Asc	Para	✓	✓	R			initially sensitive				

Dx = diagnosis  
P = passage  
✓ = confirmed, t = currently testing  
T = tumor  
Asc = ascites  
OV= Ovary, OM = Omentum, Para= paracentesis  
P= Primary, R= Recurrent, <sup>PR</sup>= platinum resistant  
A = Adjuvant, N = Neo-adjuvant